Davita Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.24 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 14.9× Davita Inc's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Vanguard Emerging Markets Stock Index Fund ETF for 134 Days on average.
| DVA | VWO | |
|---|---|---|
Market Cap | $11.29B | $168.50B |
Volume | 582,204 | 9,650,999 |
Sector | Health | — |
52-Week High | $240.96 | $61.44 |
52-Week Low | $103.87 | $52.42 |
Typical Hold Time | 113 Days | 134 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
VWO trades at $59.85, down 1.27% with a bearish technical signal. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic weakness creates headwinds. Institutional ownership has increased with Allianz Asset Management growing its stake by 12.6% in Q3 2026, though technical indicators show selling pressure outweighing buying signals.
The outlook remains cautious with emerging markets facing economic divergence. Opportunities exist in semiconductor and technology exposure, but risks include China's property slump and currency volatility. Wall Street sentiment is neutral with the ETF trading near key support levels amid global market uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →